医学
免疫系统
癌症
不利影响
免疫检查点
封锁
癌症治疗
易普利姆玛
无容量
免疫疗法
免疫学
内科学
受体
作者
Takeo Fujii,Aung Naing,Christian Rolfo,Joud Hajjar
标识
DOI:10.1016/j.critrevonc.2018.07.010
摘要
Immune checkpoint inhibitors (ICPis) are emerging as the new corner stone of cancer treatment due to their ability to produce durable responses in patients with various cancers. But, objective responses to ICPis vary among each type of cancer. Further, treatment with ICPis is often associated with risk of developing immune-related adverse event, which are potentially life-threatening if untreated, indicating a need for patient selection. However, given the complexity of the tumor microenvironment and the dynamic interaction between tumor and immune cells, development of robust biomarkers to predict patients who are likely to respond to treatment with ICPis remains a challenge. In this review we present an overview of the immune monitoring strategies that are currently in use to enable appropriate patient selection.
科研通智能强力驱动
Strongly Powered by AbleSci AI